JPWO2020230091A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020230091A5
JPWO2020230091A5 JP2021567974A JP2021567974A JPWO2020230091A5 JP WO2020230091 A5 JPWO2020230091 A5 JP WO2020230091A5 JP 2021567974 A JP2021567974 A JP 2021567974A JP 2021567974 A JP2021567974 A JP 2021567974A JP WO2020230091 A5 JPWO2020230091 A5 JP WO2020230091A5
Authority
JP
Japan
Prior art keywords
egfr
cancer
seq
administered
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021567974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022531980A (ja
JP2022531980A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/054594 external-priority patent/WO2020230091A1/en
Publication of JP2022531980A publication Critical patent/JP2022531980A/ja
Publication of JPWO2020230091A5 publication Critical patent/JPWO2020230091A5/ja
Publication of JP2022531980A5 publication Critical patent/JP2022531980A5/ja
Priority to JP2025060710A priority Critical patent/JP2025118606A/ja
Pending legal-status Critical Current

Links

JP2021567974A 2019-05-14 2020-05-14 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 Pending JP2022531980A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025060710A JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847605P 2019-05-14 2019-05-14
US62/847,605 2019-05-14
PCT/IB2020/054594 WO2020230091A1 (en) 2019-05-14 2020-05-14 Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025060710A Division JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Publications (3)

Publication Number Publication Date
JP2022531980A JP2022531980A (ja) 2022-07-12
JPWO2020230091A5 true JPWO2020230091A5 (https=) 2023-07-11
JP2022531980A5 JP2022531980A5 (https=) 2023-07-11

Family

ID=78716450

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021567974A Pending JP2022531980A (ja) 2019-05-14 2020-05-14 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法
JP2025060710A Pending JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025060710A Pending JP2025118606A (ja) 2019-05-14 2025-04-01 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法

Country Status (12)

Country Link
EP (1) EP3968985A4 (https=)
JP (2) JP2022531980A (https=)
KR (1) KR20220010731A (https=)
CN (1) CN113840601A (https=)
AU (1) AU2020275272A1 (https=)
BR (1) BR112021022828A2 (https=)
CA (1) CA3140360A1 (https=)
EA (1) EA202193117A1 (https=)
IL (1) IL287962A (https=)
MA (1) MA55978A (https=)
MX (1) MX2021013955A (https=)
SG (1) SG11202112412QA (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024346227A1 (en) * 2023-09-21 2026-04-09 Beijing Neox Biotech Limited Multi-specific antibodies and uses thereof
TW202519556A (zh) * 2023-09-28 2025-05-16 大陸商上海翰森生物醫藥科技有限公司 雙特異性抗體在製備治療癌症的藥物中的用途
CN120271706A (zh) * 2023-12-29 2025-07-08 上海安领科生物医药有限公司 抗egfr单抗、其双特异性抗体、药物组合物和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
RU2601892C2 (ru) * 2008-03-06 2016-11-10 Дженентек, Инк. Комбинированная терапия антагонистами с-мет и egfr
DK2560993T3 (da) * 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN113201073A (zh) * 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP3929190B1 (en) * 2014-10-13 2024-12-25 Yuhan Corporation Compounds and compositions for modulating egfr mutant kinase activities
AR111469A1 (es) * 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
SG11202108311RA (en) * 2019-02-26 2021-09-29 Janssen Biotech Inc Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies

Similar Documents

Publication Publication Date Title
JP2024153659A5 (https=)
KR102905497B1 (ko) 항체-약물 컨쥬게이트와 parp 저해제의 조합
JP2024102215A5 (https=)
JP2024161445A (ja) 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
US20250064967A1 (en) Combination of antibody-drug conjugate and atr inhibitor
TW202216208A (zh) 抗體-藥物結合物及atr抑制劑之組合
WO2019096194A1 (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN101998851A (zh) 吡铂和西妥昔单抗治疗结直肠癌的用途
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
JP2020114849A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
JP2023513297A (ja) ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
ES2806073T3 (es) Nuevas composiciones farmacéuticas que comprenden un anticuerpo que se une al receptor humano de la hormona antimulleriana de tipo II
JPWO2020174370A5 (https=)
CN117940169A (zh) 抗体药物偶联物的用途及联合用药物及其用途
US20250025568A1 (en) Combination of antibody-drug conjugate and parp1 selective inhibitor
WO2021063340A1 (zh) Ezh2抑制剂与免疫检查点抑制剂、酪氨酸激酶抑制剂联合在制备治疗肿瘤药物中的用途
JPWO2020230091A5 (https=)
ES3049048T3 (en) Quinoline derivative and antibody toripalimab soft tissue sarcoma combination therapy
CN116568306A (zh) 用于治疗实体瘤的包含krasg12c抑制剂和egfr抑制剂的方法和组合物
JPWO2021161262A5 (https=)
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
JP2022522328A (ja) Ｓｕｍｏ活性化酵素阻害剤及びチェックポイント阻害剤の投与
JPWO2022043895A5 (https=)
JP7540946B2 (ja) アシルチオウレア化合物とアビラテロンの併用療法
CN118019537A (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途